source
- J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotechThe in vivo CAR-T space is getting more competitive as one of the biggest cell therapy players expands its role. Johnson & Johnson is paying $785 million upfront to work with Flagship Pioneering's…Endpoints · 35m ago↗ source
- FDA approves first freeze-dried plasma product for U.S. useThe FDA has licensed Ezplaz Freeze Dried Plasma (FDP), marking the first freeze-dried plasma product cleared for use in the United States. The product is intended for adult patients who need plasm…